Abstract:The potential pathogenetic mechanisms underlying the varied morphology of congenital pulmonary airway malformations (CPAMs) have not been molecularly determined, but a subset have been shown to contain clusters of mucinous cells (MCC). These clusters are believed to serve as precursors for potential invasive mucinous adenocarcinoma, and they are associated with KRAS codon 12 mutations. To assess the universality of KRAS mutations in MCCs, we sequenced exon 2 of KRAS in 61 MCCs from 18 patients, and we found a KRAS codon 12 mutation in all 61 MCCs. Furthermore, all MCCs from a single patient always had the same KRAS mutation, and the same KRAS mutation was also found in non-mucinous lesional tissue. Next generation sequencing of seven MCCs showed no other mutations or copy number variations. Sequencing of 46 additional CPAMs with MCCs revealed KRAS mutations in non-mucinous lesional tissue in all cases. RNA in situ hybridization confirmed widespread distribution of cells with mutant KRAS RNA, even extending outside of the bronchiolar type epithelium. We identified 25 additional CPAMs with overall histologic architecture similar to CPAMs with KRAS mutations but without identifiable MCCs, and we found KRAS mutations in 17 (68%). The histologic features of these KRAS mutated CPAMs included type 1 and type 3 morphology, as well as lesions with an intermediate histologic appearance, and analysis revealed a strong correlation between the specific amino acid substitution and histomorphology. These findings, together with previously published model organism data, suggests that the formation of type 1 and 3 CPAMs is driven by mosaic KRAS mutations arising in the lung epithelium early in development and places them within the growing field of mosaic RASopathies. The presence of widespread epithelial mutation explains late metastatic disease in incompletely resected patients and reinforces the recommendation for complete resection of these lesions.

Neurodevelopmental Aspects of RASopathies

RASopathies influences on neuroanatomical variation in children.

Developmental effect of RASopathy mutations on neuronal network activity on a chip

Non-Mammalian Models for Understanding Neurological Defects in RASopathies

[New Insight of Craniofacial and Oral Findings of the RASopathies].

Defining the spatial landscape of KRAS mutated congenital pulmonary airway malformations: a distinct entity with a spectrum of histopathologic features

-mutant Schwann cells divert to a repair phenotype to induce congenital demyelinating neuropathy

RASopathies for Radiologists

RASopathies Due to De Novo Pathogenic Variants: Clinical Features, Genetic Findings and Outcomes in Nine Neonates Born with Congenital Heart Defects

RAS pathway: The new frontier of brain mosaicism in epilepsy

Interactions between Ras and Rap signaling pathways during neurodevelopment in health and disease

Syndromic craniosynostosis caused by a novel missense variant in MAP4K4: Expanding the genotype–phenotype relationship in RASopathies

Targeting RAS in neuroblastoma: Is it possible?

Biomarker Landscape in RASopathies

Deletion of MAP2K2/MEK2: a novel mechanism for a RASopathy?

Cardiac Phenotype and Gene Mutations in RASopathies

Pathophysiological Mechanisms in Neurodevelopmental Disorders Caused by Rac GTPases Dysregulation: What’s behind Neuro-RACopathies

Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders

Cardiac Manifestations and Associations with Gene Mutations in Patients Diagnosed with RASopathies

Targeting Hyperactive Ras Signaling in Pediatric Cancer